- RO 20-1724
-
- $15.00 / 1KG
-
2021-08-12
- CAS:29925-17-5
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | RO 20-1724 Basic information |
| | RO 20-1724 Chemical Properties |
| Melting point | 125-127° | | Boiling point | 483.8±25.0 °C(Predicted) | | density | 1.099±0.06 g/cm3(Predicted) | | storage temp. | room temp | | solubility | ethanol: 7 mg/mL | | form | solid | | pka | 14.54±0.40(Predicted) | | color | White | | biological source | synthetic (organic) | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 6 months. | | CAS DataBase Reference | 29925-17-5(CAS DataBase Reference) |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | WGK Germany | 3 |
| | RO 20-1724 Usage And Synthesis |
| Description | RO 20-1724 (29925-17-5) is a selective inhibitor of cAMP-specific phosphodiesterase (PDE4), IC50 = 0.2 μM. Displays anti-inflammatory activity. Cell permeable | | Uses | Ro 20-1724 is a cell-permeable, cAMP-specific phosphodiesterase type IV (PDE4) inhibitor (IC50 = 2 μM). It weakly inhibits PDE3 with a Ki value greater than 25 μM. Ro 20-1724 inhibits the release of cytokines and other inflammatory signals as well as prevents the development of reactive oxygen species. It is often used to study cAMP-related functions in vascular cells. | | Uses | Ro 20-1724 Is an inhibitor of phosphodiesterase-4, and also very effective for patients with plaque psoriasis. Selective inhibitor of cAMP-specific phosphodiesterase. Selective PDE4 inhibitor. | | Definition | ChEBI: 4-[(3-butoxy-4-methoxyphenyl)methyl]-2-imidazolidinone is a member of methoxybenzenes. | | Biological Activity | Widely used inhibitor of cyclic nucleotide phosphodiesterase, selective for PDE4 (IC 50 = 2.0 μ M). Also available as part of the Phosphodiesterase Inhibitor Tocriset™ . | | Biochem/physiol Actions | Inhibitor of cAMP phosphodiesterase. IC50 33 μM in vascular smooth muscle of the aorta. | | storage | Store at RT | | References | [1] S H SODERLING J A B S J Bayuga. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase.[J]. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95 15: 8991-8996. DOI:10.1073/pnas.95.15.8991
[2] C D NICHOLSON M S R A Challiss. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.[J]. Trends in pharmacological sciences, 1991, 12 1: 19-27. DOI:10.1016/0165-6147(91)90484-a |
| | RO 20-1724 Preparation Products And Raw materials |
|